Badania kliniczne prowadzone w ośrodku Medicover Integrated Clinical Services Sp. z o.o. (Ul. Jana Karola Chodkiewicza 19c, Bydgoszcz), które rekrutują lub wkrótce zaczną rekrutację. Dane pochodzą z rejestrów badań.
30 badań: 29 rekrutuje, 1 wkrótce zacznie.
Ośrodek niezweryfikowany
Medicover Integrated Clinical Services Sp. z o.o.
Ul. Jana Karola Chodkiewicza 19c
Bydgoszcz
Otwórz w Mapach Google · OpenStreetMap
Ośrodek niezweryfikowany. Nazwa, adres i lista badań pochodzą z publicznych rejestrów badań klinicznych (CTIS, ClinicalTrials.gov). Ośrodek nie potwierdził tych danych z nami. Przed wizytą zadzwoń do nas, a nasz doradca sprawdzi aktualne informacje.
Mapa: © autorzy OpenStreetMap
Wpisz słowo, żeby przeszukać wszystkie 30 badań.
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized…
+1A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
+14Study of Aritinercept in Patients With Generalized Myasthenia Gravis
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
+29A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
+2ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
+20ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a…
+2A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
+17Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
+27A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
+6Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
+22A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
+28A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
+1A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
+4A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
+29Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
+19A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
+4Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
+3A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
+8Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
+24A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
+25A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
+5MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical…
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.